Top Stock Picks 2014

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of oil and gas service company Core Laboratories (NYSE: CLB  ) jumped as much as 10% today after the company released first quarter earnings.

So what: Revenue rose 11.4% in the quarter, to $260.9 million, and net income was up 4.8% from a year ago to $56.5 million, or $1.22 per share. Analysts expected revenue of $245.0 million and earnings of $1.15 per share, so the results easily passed Wall Street's view.�

Now what: The reservoir management segment was the most impressive, with revenue up 32%, and operating income rising 24%. Oil and gas are becoming harder to find and harder to evaluate, so the services that Core Labs provides are crucial to the industry. Shares are now trading at 23 times forward earnings, not a steal given the company's growth level, but I still think shares can move higher after another positive quarter.

Interested in more info on Core Laboratories? Add it to your watchlist by clicking here.

Best Defensive Stocks To Buy For 2015: Allergan Inc. (AGN)

Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment offers a range of pharmaceutical products, including ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, allergy, and retinal diseases; Botox for the therapeutic and aesthetic indications; skin care products for acne, psoriasis, and other skin care products; eyelash growth products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery; obesity intervention products, including the La p-Band System and the Orbera Intragastric Balloon System; and facial aesthetics products. The company also offers Contigen for the treatment of urinary incontinence due to intrinsic sphincter deficiency. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, and ambulatory surgery centers, as well as to medical practitioners, including ophthalmologists, neurologists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, pediatricians, urologists, and general practitioners. Allergan, Inc. has strategic research collaboration agreements with ExonHit Therapeutics S.A.; Spectrum Pharmaceuticals, Inc.; and Pieris AG. The company was founded in 1948 and is headquartered in Irvine, California.

Advisors' Opinion:

• [By Keith Speights]

  First, the good news. ACADIA stated on Monday that its partner Allergan (NYSE: AGN  ) advanced another new chemical entity from the two companies' collaboration into pre-clinical development. ACADIA's CEO, Dr.��Uli Hacksell, said the molecule has "distinctly different properties from other glaucoma compounds" previously advanced by Allergan. The two companies first partnered on development of new treatments for glaucoma back in 2003.

• [By Steven Russolillo]

  WATCH FOR: First-Quarter Productivity (8:30 a.m. Eastern Time): seen -1.1%; previously +1.8%. First-Quarter Unit Labor Costs (8:30): seen +2.8%; previously -0.1%. March Consumer Credit (3:00): seen +$16.1 B; previously $16.5B. Allergan(AGN), AOL(AOL), Avis Budget(CAR), CenturyLink, Chesapeake Energy(CHK), CF Industries(CF), Devon Energy(DVN), Duke Energy(DUK), Dynergy, Hertz, Humana, Keurig Green Mountain(GMCR), Lamar Advertising(LAMR), Molson Coors/Miller, Mondelez, Prudential, SolarCity(SCTY), Sotheby's(BID), Tesla Motors(TSLA), Transocean and 21st Century Fox are among companies scheduled to report quarterly results.

• [By Jayson Derrick]

  Analysts at Barclays maintained an Equal-weight rating on Allergan (NYSE: AGN) with a price target raised to $130 from a previous $95. Shares gained 0.86 percent, closing at $127.96.

Top Stock Picks 2014: Ascent Media Corporation(ASCMA)

Ascent Capital Group, Inc., through its subsidiary, Monitronics International, Inc., provides security alarm monitoring and related services to residential and business subscribers in the United States and Canada. The company is involved in monitoring signals arising from burglaries, fires, medical alerts, and other events, as well as provides customer service and technical support. It also provides central station monitoring services on a wholesale basis for other independent alarm companies that do not have the capability to monitor systems for their customers. In addition, Ascent Capital Group, Inc. offers a range of residential security services, including hands-free two-way voice communication with the monitoring center, cellular options, and an interactive service option, which allows the customer to control their security system using a computer or smart phone. The company markets its services through a network of authorized dealers. Ascent Capital Group, Inc. is ba sed in Greenwood Village, Colorado.

Advisors' Opinion:

• [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

  Both of these stocks are overlooked, undervalued, and cash flow machines. The companies are Ascent Capital Group (ASCMA) and Covanta Holdings (CVA).

Top Stock Picks 2014: BioDelivery Sciences International Inc.(BDSI)

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products. The BEMA technology is a small erodible polymer film for application to the buccal mucosa; and the Bioral cochleate drug delivery technology encapsulates a selected drug or therapeutic in a cochleate cylinder. Its pain franchise consists of products utilizing the patented BEMA technology, including ONSOLIS, a fentanyl buccal soluble film for the management of pain in opioid tolerant adult patients with cancer; and BEMA Buprenorphine, which is in the development stage for the treatment of moderate to severe chronic pain, as well as for the treatment of opioid dependence. The company also engages in developing product candidates utilizing the B EMA technology for conditions, such as nausea/vomiting. BioDelivery Sciences International, Inc. was founded in 1997 and is headquartered in Raleigh, North Carolina.

Advisors' Opinion:

• [By Lisa Levin]

  BioDelivery Sciences International (NASDAQ: BDSI) shares climbed 5.61% to $12.05. The volume of BioDelivery Sciences shares traded was 332% higher than normal. BioDelivery Sciences shares have jumped 165.97% over the past 52 weeks, while the S&P 500 index has gained 20.55% in the same period.

• [By Garrett Cook]

  BioDelivery Sciences International (NASDAQ: BDSI) shares shot up 12.43 percent to $13.48 on positive top-line Phase III results.

  Shares of Kandi Technolgies Group (NASDAQ: KNDI) got a boost, shooting up 5.43 percent to $14.76 after the company announced a subsidy of $31.8 million for sales of more than 3,000 electric vehicles between June and December of 2013.

• [By Garrett Cook]

  BioDelivery Sciences International (NASDAQ: BDSI) shares shot up 9.17 percent to $13.09 on positive top-line Phase III results.

  Shares of Kandi Technolgies Group (NASDAQ: KNDI) got a boost, shooting up 6.36 percent to $14.89 after the company announced a subsidy of $31.8 million for sales of more than 3,000 electric vehicles between June and December of 2013.

Top Stock Picks 2014: Limelight Networks Inc.(LLNW)

Limelight Networks, Inc. provides content delivery network services in North America, Europe, the Middle East, Africa, and the Asia Pacific. It offers content delivery services to deliver media files, such as video, music, games, and software, or live streaming of corporate or entertainment events; video content management services, which enable organizations to publish, manage, syndicate, analyze, and monetize video content through a cloud-based service; Web content management services that enable content publishers to create, manage, and publish Web content through a cloud-based service; and mobility and monetization services that help publishers to deliver content to media-enabled mobile handsets or tablets. The company also provides Web acceleration services, which enhance Web experiences for content, online commerce transactions, and Web applications; cloud storage services that comprise customer services for the storage of media and enterprise content; and global con sulting and technical services that enable customers optimize their publishing, e-commerce, mobility, or content distribution workflows, as well as to provide support for network architecture design, storage infrastructure, Web application development, creative design, live event execution, and design, deployment, and management of infrastructure. In addition, it offers reporting and analytics services that help customers to manage and configure content delivery and presentation. The company offers its services to traditional and emerging media companies or content providers, including businesses operating in the television, music, radio, newspaper, magazine, movie, videogame, software, and social media industries; and enterprises, technology companies, and government entities doing business online. The company was founded in 2001 and is headquartered in Tempe, Arizona.

Advisors' Opinion:

• [By Bryan Murphy]

  For Google, the shift in the way the justice system looks at and handles patent infringement claims meant its subsidiary, Motorola Mobility, unsuccessfully bid to convince U.S. courts that Apple Inc. (NASDAQ:AAPL) was illegally using Google's/Motorola's approach for sending data to a mobile device. For Akamai Technologies, it means that the technology company will need to re-explain - and ultimately re-prove - to an appellate court that Limelight Networks, Inc. (NASDAQ:LLNW) infringed on an Akamai patent even though a lower court had already ruled in favor of AKAM. And for Soverain Software, the legal system's new attitude meant it wouldn't even bother hearing its appeal for a case it lost against Newegg last year... a case it's tried against several companies, losing every time.

• [By Rich Smith]

  Tempe, Ariz.-based Limelight Networks (NASDAQ: LLNW  ) will soon have a new CFO.

  On Wednesday, Limelight announced that current Chief Financial Officer Douglas Lindroth has entered a "transition period," after which he plans to leave the company to "pursue other business and professional interests." Replacing him will be new CFO Peter Perrone, who comes from Goldman Sachs' Merchant Banking Division, having experience in Internet infrastructure companies such as Limelight. He is a current member of Limelight's board of directors. He will step down from the Limelight board as he joins the firm as a senior vice president.

• [By jaggom]

  Akamai (AKAM) and Limelight (LLNW) are two completely different prospects that investors can consider in the content delivery services space. Both have been performing differently. Let's take a look at which one suits investors' portfolios the best.

Top Stock Picks 2014: Aegon NV(AEG)

AEGON N.V. provides life insurance, pensions, and asset management products and services worldwide. The company?s life insurance products include traditional, term, universal, whole, and other life insurance products sold as part of defined benefit pension plans, endowment policies, post-retirement annuity products, and group risk products; supplemental health insurance products comprise accidental death, other injury, critical illness, hospital indemnity, medicare supplement, and student health; specialty lines consists of travel, membership, and creditor products; and long term care insurance products for policyholders who require care due to a chronic illness or cognitive impairment. It also offers a range of savings and retirement products and services, including mutual funds, and fixed and variable annuities, savings accounts and investment contracts, segregated funds, guaranteed investment accounts, and single premium immediate annuities, as well as investment advice to individuals. In addition, the company offers employer solutions and pensions, such as retirement plans, pension plans, and pension-related products and services; investment products, including onshore and offshore bonds, and trusts; reinsurance products and solutions to life insurance and financial services companies; general insurance products comprising house, car, and fire insurance; and asset management products and services, including general account assets, unit-linked funds, and third party activities. AEGON N.V. markets its products through independent and career agents, financial planners, registered representatives, independent marketing organizations, banks, broker-dealers, benefit consulting firms, wirehouses, affinity groups, institutional partners, independent managing general agencies, and specialized financial advisors, as well as through online, direct, and worksite marketing. The company was founded in 1900 and is headquartered in The Hague, the Netherl ands.

Advisors' Opinion:

• [By Will Ashworth]

  Assuming it delivers on its outlook for 2014, its current free cash flow yield is a very enticing 20%. This isn�� a growth stock, but its brands still possess hidden value. As cheap stocks go, it�� very attractive.

  Cheap Stocks to Buy: Aegon (AEG)

  It�� not often that you can buy a $19 billion market cap for under 10 bucks. Aegon�� a Dutch insurance company that�� had a rough ride over the past few years, and its stock�� suffered as a result. In the late ’90s AEG stock traded around $60 — it hasn�� been anywhere close since. However, it�� got some good assets that should bear fruit in the years to come. Aegon has 12,000 employees in the Americas doing business primarily under the Transamerica brand, which has been a part of AEG since 1999.

Top Stock Picks 2014: Savient Pharmaceuticals Inc(SVNT)

Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It sells its products directly to drug wholesalers. The company, formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey.

Advisors' Opinion:

• [By James E. Brumley]

  Since 2008's implosion from the stock, the interest in Savient Pharmaceuticals Inc. (NASDAQ:SVNT) has been waning. There was a brief burst of bullishness in September of last year, which stirred the bullish pot a little. But, when SVNT started to fade in October of that year - just as quickly as it had perked up - what lingering hopes there were for the stock finally started to melt away. By the middle of this year, pretty much everyone had written Savient Pharmaceuticals off as a lost cause. Big mistake. Over the last few days, SVNT has almost wiggled its way buck into a bullish zone.

• [By James E. Brumley]

  It's still too soon to say Savient Pharmaceuticals Inc. (NASDAQ:SVNT) is off and running. In fact, the stock's decidedly NOT off and running yet. But, it's not too soon to put SVNT on your watchlist of potential breakout candidates, as it's much closer to a breakout than most anyone can see.

Top Stock Picks 2014: NuPathe Inc.(PATH)

NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The company?s advanced product candidate includes Zelrix an active single-use transdermal sumatriptan patch that is used for the treatment of migraine. Its proprietary product candidates in preclinical development stage comprise NP201 for the continuous symptomatic treatment of Parkinson?s disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. NuPathe Inc. was founded in 2005 and is headquartered in Conshohocken, Pennsylvania.

Advisors' Opinion:

• [By Tess Stynes]

  Endo Health Solutions Inc.(ENDP) agreed to acquire pharmaceutical company NuPathe Inc.(PATH) for about $105 million to gain the company’s new migraine treatment. Endo will acquire NuPathe for $2.85 per share, a 24% premium to its close of $2.30 on Friday. NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if the company’s migraine treatment Zecuity meets certain sales milestones. NuPathe shares were up 51% at $3.48 in premarket trading.

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Tuesday’s session are Delta Air Lines Inc.(DAL), NuPathe Inc.(PATH) and YRC Worldwide Inc.(YRCW)

• [By Vanina Egea] lli revealed owning a stake of 1,313,500 NuPathe Inc. shares, worth 0.01% of his portfolio. NuPathe Inc. has a market cap of $142 million; its shares are trading currently at around $4.3 with a P/B ratio of 18.4.

  NuPathe is a specialty pharmaceutical company, focusing on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. Teva Pharmaceutical Industries Ltd. (TEVA) announced a tender offer for all of the outstanding shares of common stock at a price of $3.65 per share in cash, and NuPathe stockholders will receive rights to receive additional cash payments of up to $3.15 per share The firm will become a wholly owned subsidiary of Teva, and common stock will cease to be traded on the Nasdaq following completion of the merger.

  Hedge fund gurus have also been active in the company: Jim Simons (Trades, Portfolio) and Ronald Muhlenkamp (Trades, Portfolio) have invested in it.

  ATMI Inc. (ATMI)

  Gabelli reported a stake of 1,193,900 shares of ATMI Inc., sized at 0.22% of his portfolio, and 3.75% of the company. It has a market cap of $1.08 billion; its shares are trading at $34.04 with a P/E ratio of 28.6 and P/S ratio of 2.77.

  ATMI supplies high performance materials, materials packaging and materials delivery systems for use in the manufacture of microelectronics devices worldwide. ATMI agreed to be acquired by Entegris (ENTG) for $1.15 billion, or $34 per share. The deal will provide a lot more of product offerings. The acquisition is expected to close during the second calendar quarter of 2014.

  Hedge fund gurus have also been active in the company. Jim Simons (Trades, Portfolio), Arnold Schneider (Trades, Portfolio) and Paul Tudor Jones (Trades, Portfolio) have divested in it in the last quarter.

  Nobility Homes Inc. (NOBH)

  Finally, Gabelli reported owning 234.950 shares of Nobility Homes, sized at 5.97% of the company�� shares outstanding and 0.01% of Gabelli�

• [By James E. Brumley]

  It's not hard to find an attractive stock with the market is rallying - the rising tide lifts all stocks. The real test for a ticker is when the whole market is tanking (like Thursday), and a stock manages to make gains against the grain. Enter NuPathe Inc. (NASDAQ:PATH). This little biopharma stock is up 3% today, which isn't much, but given the market it's a virtual windfall. It's the reason for the rally - or lack of a reason to be more specific - that makes PATH such a compelling buy here.